Molecular Partners posts Gordon Research Conference Radio-DARPins presentation on website

(AWP Alliance News) - Molecular Partners published a presentation from the Gordon Research Conference on radionuclide theranostics outlining its bispecific Radio-DARPin approach to radioligand therapy. The materials describe using multispecific formats to address tumor heterogeneity by engaging multiple tumor targets, with designs spanning bispecific constructs or a 2-in-1 DuoDARPin that can bind two targets in an either/or manner.

The presentation also highlights MP0712, a DLL3-targeting Radio-DARPin in a US Phase 1/2a trial, with MP0726, a mesothelin-targeting candidate, expected to reach first human imaging this year. The presentation is posted on the company site under Scientific Documents at https://www.globenewswire.com/Tracker?data=0ijaRS3ZoAuXpGMjEn_BNdIhA1xh….

https://www.globenewswire.com/NewsRoom/ReleaseNg/7706305

Disclaimer: This news brief was created using generative artificial intelligence. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire on July 15, 2026, and is solely responsible for the information contained therein.